Stifel Maintains Buy on DexCom, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman maintains a Buy rating on DexCom and raises the price target from $90 to $100.
August 23, 2024 | 11:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Mathew Blackman has reiterated a Buy rating for DexCom and increased the price target from $90 to $100, indicating confidence in the company's future performance.
The increase in the price target from $90 to $100 by Stifel suggests a positive outlook on DexCom's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100